<DOC>
	<DOCNO>NCT01873326</DOCNO>
	<brief_summary>The purpose study learn safety effectiveness two different drug combination patient intermediate- poor-risk germ cell tumor ( GCT ) . One combination drug , paclitaxel , ifosfamide cisplatin ( TIP ) , experimental . The combination drug , bleomycin , etoposide cisplatin ( BEP ) , standard care treatment intermediate- poor-risk germ cell tumor . However , BEP cure every patient therefore new treatment need .</brief_summary>
	<brief_title>Paclitaxel , Ifosfamide Cisplatin ( TIP ) Versus Bleomycin , Etoposide Cisplatin ( BEP ) Patients With Previously Untreated Intermediate- Poor-risk Germ Cell Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Patients ≥ 18 year age . Patients newly diagnose GCT Pathology confirmation GCT histology MSKCC collaborate treat institution . In exceptional circumstance , patient without pathological diagnosis may include study follow discussion national principal investigator , Dr. Feldman , ( national CoPI MSKCC CoPI national PI unavailable ) meet one follow criterion : Patients testicular mass ( detect clinically and/or ultrasound ) , and/or mediastinal retroperitoneal lymphadenopathy pineal tumor AND elevate serum tumor marker ( HCG and/or AFP ) . Patients elevate LDH include without pathological confirmation GCT since LDH nonspecific marker GCT could potentially elevated malignancy lymphomas . This patient may present clinical scenario consistent GCT ( elevate serum tumor marker , testicular mass retroperitoneal lymphadenopathy ) concurrent lifethreatening oncologic emergency require immediate treatment . In case , initial treatment without biopsy confirmation usually recommend tissue confirmation may obtain initiate therapy . Patients must measurable evaluable disease . Patients must classify intermediate poorrisk germ cell tumor , follow : Intermediaterisk ( Modified* ) ) Testis retroperitoneal primary NSGCT lymph node and/or lung metastasis without nonpulmonary visceral metastasis AND follow pretreatment serum tumor marker ( STM ) value : i. Lactate dehydrogenase ( LDH ) 3 &lt; 10 x ULN ( *This differs original IGCCCG criterion include patient LDH 1.5 10 x ULN ) . ii . Serum human chorionic gonadotrophin ( HCG ) 5,000 &lt; 50,000 MIU/mL iii . Serum alphafetoprotein ( AFP ) 1,000 &lt; 10,000 ng/mL b ) Seminoma histology regardless primary site serum tumor marker nonpulmonary visceral metastasis ( liver , bone , brain , etc ) . Poorrisk ( follow ) : 1 . Testis retroperitoneal NSGCT primary nonpulmonary visceral metastasis ( liver , bone , brain , etc ) regardless STM value . 2 . Mediastinal NSGCT primary site disease regardless presence/absence visceral metastasis STM value . 3 . Testis retroperitoneal NSGCT primary without nonpulmonary visceral metastasis poorrisk STM value : i. LDH ≥ 10 x ULN ii . HCG ≥ 50,000 MIU/mL iii . AFP ≥ 10,000 ng/mL Patients receive prior radiation therapy ( RT ) treatment germ cell tumor eligible study long evidence progressive disease determine tumor marker sit metastasis outside radiate site . Radiation must complete prior start chemotherapy exception brain metastasis chemotherapy radiation give concurrently . Toxicity radiation must recover grade 1 less prior initiating chemotherapy . Patients must recover prior surgery base treat physician 's discretion . Patients reproductive potential must agree use effective contraception period therapy Signed informed consent . Diffusion lung capacity carbon monoxide ( DLCO ) adjust hemoglobin ≥60 % predict , except related high volume metastatic GCT lung case minimum DLCO requirement . In case , patient may able undergo PFT test due severity presentation . high volume lung metastasis tumorrelated pain ( large mediastinal mass , pleural disease , etc . ) limit ability complete PFTs . Even PFTs complete case , patient still eligible low DLCO attribute directly patient 's disease ( e.g. , large mediastinal mass ) rather intrinsic lung disease . Since minimum DLCO patient , extraordinary circumstance , allow . Most patient situation expect receive diseasestabilizing chemotherapy . An unadjusted DLCO may use place DLCO adjust hemoglobin certain situation per institutional policy . For example , MSKCC policy adjust DLCO hemoglobin hemoglobin ≥ 14.6 g/dL male ≥ 13.4 g/dL female . In case , unadjusted DLCO must &gt; 60 % predict . Laboratory criterion protocol entry ( obtain ≤ 14 day initiation therapy ) : WBC ≥ 3000/UL Platelet count ≥ 100,000/UL Serum creatinine ≤ 1.5 mg/dL estimate GFR ( CockcroftGault ) ≥50mL/min 12 24 hour urine creatinine clearance ≥ 50 mL/min , unless renal insufficiency due tumoral ureteral obstruction case eligibility determine national principal investigator ( national coPI MSKCC coPI national PI unavailable ) notification MSKCC IRB . AST/ALT ≤ 3 x ULN total bilirubin ≤ 2.0 x ULN . In set metastatic disease liver , AST/ALT may ≤5x ULN total bilirubin ≤2.5 x ULN . If patient know suspect Gilbert 's disease , total bilirubin ≤2.5 x ULN allow . Any prior chemotherapy . The exception patient history stage I seminoma treat adjuvant carboplatin 1 2 cycle . Concurrent treatment cytotoxic therapy . Known concurrent malignancy ( except nonmelanoma skin cancer ) . Patients know HIV positive receive HAART . Presence active infection . Patients fever assess `` tumor fever '' without active evidence infection ( e.g . blood culture negative ) eligible . In addition , patient infection without evidence fever 48 hour antibiotic eligible . Inability comply treatment protocol undergo prespecified followup test safety effectiveness . Pregnant patient ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>newly diagnose GCT</keyword>
	<keyword>Intermediate</keyword>
	<keyword>Poor-Risk</keyword>
	<keyword>BLEOMYCIN</keyword>
	<keyword>CISPLATIN</keyword>
	<keyword>ETOPOSIDE ( VP-16 )</keyword>
	<keyword>IFOSFAMIDE</keyword>
	<keyword>TAXOL ( PACLITAXEL )</keyword>
	<keyword>13-074</keyword>
</DOC>